Hydrochlorothiazide
- Generic Name
- Hydrochlorothiazide
- Brand Names
- Accuretic, Actelsar Hct, Aldactazide, Altace HCT, Atacand, Atacand Hct, Avalide, Benicar Hct, Diovan Hct, Exforge Hct, Hyzaar, Ifirmacombi, Karvezide, Lopressor Hct, Lotensin Hct, Maxzide, Micardis-hct, Olmetec Plus, Tekturna Hct, Teveten HCT, Tribenzor, Urozide, Vaseretic, Viskazide, Zestoretic, Ziac
- Drug Type
- Small Molecule
- Chemical Formula
- C7H8ClN3O4S2
- CAS Number
- 58-93-5
- Unique Ingredient Identifier
- 0J48LPH2TH
- Background
Hydrochlorothiazide is the most commonly prescribed thiazide diuretic. It is indicated to treat edema and hypertension. Hydrochlorothiazide use is common but declining in favour of angiotensin converting enzyme inhibitors. Many combination products are available containing hydrochlorothiazide and angiotensin converting enzyme inhibitors or angiotensin II rec...
- Indication
Hydrochlorothiazide is indicated alone or in combination for the management of edema associated with congestive heart failure, hepatic cirrhosis, nephrotic syndrome, acute glomerulonephritis, chronic renal failure, and corticosteroid and estrogen therapy. Hydrochlorothiazide is also indicated alone or in combination for the management of hypertension.
- Associated Conditions
- Calcium Nephrolithiasis, Cirrhosis of the Liver, Congestive Heart Failure (CHF), Diabetes Insipidus, Edema, Hypertension, Hypertension, Essential Hypertension, Hypokalemia caused by diuretics, Nephrotic Syndrome, Pre-Eclampsia, Premenstrual tension with edema, Renal tubular acidosis, Sodium retention, Stroke
- Associated Therapies
- -
Efficacy and Safety of Chronic Administration of Telmisartan as Monotherapy or in Combination With Hydrochlorothiazide or Other Antihypertensive Medications in Patients With Mild to Moderate Hypertension
- First Posted Date
- 2014-06-27
- Last Posted Date
- 2014-07-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 489
- Registration Number
- NCT02177422
Telmisartan/Hydrochlorothiazide (HCTZ) Fixed Dose Combination Compared to Its Monocomponents in Healthy Subjects
- First Posted Date
- 2014-06-27
- Last Posted Date
- 2014-07-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 20
- Registration Number
- NCT02176512
Efficacy and Safety of the Angiotensin II Receptor Antagonist Micardis® (Telmisartan) or Hydrochlorothiazide in the Management of Patients With Isolated Systolic Hypertension (ISH)
- Conditions
- Interventions
- First Posted Date
- 2014-06-26
- Last Posted Date
- 2014-07-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1039
- Registration Number
- NCT02175355
Telmisartan With or Without Hydrochlorothiazide (HCTZ) Compared With Losartan With or Without HCTZ in Mild to Moderate Hypertensive Patients
- Conditions
- Interventions
- First Posted Date
- 2014-06-24
- Last Posted Date
- 2014-06-24
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 363
- Registration Number
- NCT02172586
Study to Evaluate the Efficacy and Safety of Combined Administration of TAK-536CCB and Hydrochlorothiazide in Patients With Grade I or II Essential Hypertension.
- Conditions
- Interventions
- First Posted Date
- 2014-02-26
- Last Posted Date
- 2014-02-26
- Lead Sponsor
- Takeda
- Target Recruit Count
- 353
- Registration Number
- NCT02072330
Vascular Dysfunction in Human Obesity Hypertension
- Conditions
- Interventions
- First Posted Date
- 2013-11-14
- Last Posted Date
- 2023-04-14
- Lead Sponsor
- Gary L. Pierce
- Target Recruit Count
- 33
- Registration Number
- NCT01983462
- Locations
- 🇺🇸
University of Iowa, Iowa City, Iowa, United States
Add-on to Micamlo BP Trial
- Conditions
- Interventions
- First Posted Date
- 2013-11-03
- Last Posted Date
- 2016-11-29
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 309
- Registration Number
- NCT01975246
- Locations
- 🇯🇵
1348.1.022 Boehringer Ingelheim Investigational Site, Mihama-ku, Chiba, Chiba, Japan
🇯🇵1348.1.004 Boehringer Ingelheim Investigational Site, Miyagino-ku, Sendai, Miyagi, Japan
🇯🇵1348.1.025 Boehringer Ingelheim Investigational Site, Sapporo, Hokkaido, Japan
Aliskiren Study of Safety and Efficacy in Senior Hypertensives
- Conditions
- Interventions
- First Posted Date
- 2013-08-14
- Last Posted Date
- 2015-04-16
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT01922141
Pharmacokinetic Interactions of Losartan and Hydrochlorothiazide
- Conditions
- Interventions
- First Posted Date
- 2013-05-21
- Last Posted Date
- 2013-05-27
- Lead Sponsor
- Damanhour University
- Target Recruit Count
- 18
- Registration Number
- NCT01858623
Drug Interaction Between Irbesartan and Hydrochlorothiazide
- Conditions
- Interventions
- First Posted Date
- 2013-05-21
- Last Posted Date
- 2013-05-27
- Lead Sponsor
- Damanhour University
- Target Recruit Count
- 18
- Registration Number
- NCT01858610
- Locations
- 🇪🇬
Pharmaceutics Department, Faculty of Pharmacy, Damanhour University, Damanhour, Egypt
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.